• Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Research and innovation
    • Quality and certifications
    • Commitment to sport
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • Cetilar Crema
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor Relations
    • INVESTOR
      • Shares study and research
      • Share capital and Shareholders
      • Financial statements
      • Presentations
      • SDIR
      • Corporate events
      • Company presentation
      • Notice of meetings
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Shareholders’ meeting
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • Media
    • News
    • Social commitment
  • Careers
    • Work with us
    • Job offers
  • Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Research and innovation
    • Quality and certifications
    • Commitment to sport
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • Cetilar Crema
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor Relations
    • INVESTOR
      • Shares study and research
      • Share capital and Shareholders
      • Financial statements
      • Presentations
      • SDIR
      • Corporate events
      • Company presentation
      • Notice of meetings
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Shareholders’ meeting
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • Media
    • News
    • Social commitment
  • Careers
    • Work with us
    • Job offers
  • it
  • en

Shareholders’ Meeting

  • REPORT ON THE REMUNERATION POLICY AND THE REMUNERATION PAID
    April 26, 2021
  • REPORT ON CORPORATE GOVERNANCE AND OWNERSHIP STRUCTURE
    April 26, 2021
  • PROXY FORM EX ART 135 UNDECIES
    April 26, 2021
  • PROXY FORM EX ART 135 NOVIES
    April 26, 2021
  • EXPLANATORY MEMORANDUM ON REMUNERATION POLICY
    April 26, 2021
  • EXPLANATORY MEMORANDUM ON AUTHORISATION TO PURCHASE AND USE TRASURY SHARES
    April 26, 2021
  • EXPLANATORY MEMORANDUM ON FINANCIAL STATEMENTS
    April 26, 2021
  • NOTICE CONVENING THE ORDINARY SHAREHOLDERS’ MEETING OF PHARMANUTRA S.P.A
    April 26, 2021

PharmaNutra Spa

Registered office

Via Delle Lenze, 216/b - 56122 Pisa

Phone +39 050 7846500

Fax +39 050 7846524

Electronic billing code

SUBM70N

C.F. / P.Iva / Reg. Impr. 01679440501

Share capital € 1.123.097,70

I.V. | REA 146259

Contacts

Info
info@pharmanutra.it
Commerciale
commerciale@pharmanutra.it
Investor relations
investorrelation@pharmanutra.it
Distribution
internationaldept@pharmanutra.it

Product sites

sideral.it

cetilar.it

ultramag.it

apportal.it

NEWSLETTER

Subscribe to the Pharmanutra newsletter and you will be constantly updated on all our activities.
Read Newsletter Disclosure

Subscribe to the newsletter
Privacy policy Cookie policy General conditions PRIVACY INFORMATION FOR CUSTOMERS Code of ethics 231 Model

© 2020 PharmaNutra SpA - All rights reserved